ALLR · Allarity Therapeutics, Inc.

The Notice of Allowance for the stenoparib DRP® companion diagnostic patent constitutes a high-materiality intellectual property milestone for Allarity Therapeutics. Unlike routine procedural updates, this allowance covers multiple claims—including methods for predicting clinical benefit and selecting patients based on tumor-derived gene expression profiles—directly supporting the commercial and regulatory strategy for stenoparib, a dual PARP/tankyrase inhibitor currently in two Phase 2 trials for ovarian cancer and one for small cell lung cancer. The patent’s anticipated grant within three months (subject to standard USPTO procedures) and projected exclusivity through at least 2039 significantly de-risks the U.S. commercial pathway by aligning drug and diagnostic development under a single, enforceable IP umbrella—a critical advantage in precision oncology where FDA approval often requires co-development of a companion diagnostic. This allowance also strengthens Allarity’s global IP portfolio, which already includes granted patents for the stenoparib DRP® in Europe and Australia and 18 additional granted DRP® patents (eight in the U.S.) for other drugs. With stenoparib’s clinical development accelerating—particularly in platinum-resistant ovarian cancer and relapsed SCLC—the patent allowance enhances the potential value inflection point ahead of possible regulatory submissions. However, the filing explicitly cautions that actual issuance remains contingent on administrative completion and is subject to risks including challenges during prosecution or post-grant review.